Time matters! – Why PK/PD is important for oligo development
Presenter: Carl Amilon (AstraZeneca)
Date: June 10, 2020
Time: 7:00 PDT/10:00 EDT/15.00 BST/16:00 CEST/19:30 IST/22:00 CST/23:00 JST/June 11th 0:00 AEST
To register for the webinar, click here
This webinar will give an overview of how incorporating quantitative PK/PD aspects of an oligonucleotide will help you designing more informative experiments and help in translating to a human. We have all struggled with questions around the expectations of a study outcome and how to optimize the design. The talk will give you some simple to use tools and discuss common pitfalls to help you in design and interpretation of studies.
Carl Amilon was awarded his PhD in Pharmacokinetics and Pharmacodynamics from the Department of Pharmacology at the University of Gothenburg in 2013. His research focused on optimizing dosing regimen of a anti-infective drug using a PK/PD modelling. Carl joined Quantitative Clinical Pharmacology at AstraZeneca in 2013, and supported several projects in both early and late clinical development stages with a special interest in pediatric drug development. Since 2017, Carl is working as a DMPK project lead with focus on early development of drug candidates, leading work on translating preclinical data into human for all drug modalities in the AstraZeneca portfolio.